Video

Dr. Badani on Utilizing Multiport Robotic Retroperitoneal Partial Nephrectomies in RCC

Ketan K. Badani, MD, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).

Ketan K. Badani, MD, professor of urology, Icahn School of Medicine Mount Sinai, director of robotic surgery, Mount Sinai West, vice chairman, Urology and Robotic Operations, director, Comprehensive Kidney Cancer Program, Mount Sinai Health System, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC). 

Data suggest that robotic surgery is a dominant modality in cancer. Specifically, approximately 70% of all partial nephrectomies are performed robotically in the United States, Badani says. Moreover, most of these surgeries are performed through the abdomen. However, in some scenarios, such as patients with posterior-sided kidney tumors or individuals who had undergone extensive abdominal surgery and have abdominal adhesions and scarring, it is optimal to surgically go in through the retroperitoneum with a retroperitoneal partial nephrectomy, Badani explains. 

 Retroperitoneal surgeries comprise about 5% to 8% of surgeries, but up to 50% of patients could be eligible for this surgical approach because they have posterior-sided kidney tumors or have had abdominal surgeries, Badani concludes.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine